RO5263397

RO5263397, designated compound 48 in the Roche 2-aminooxazoline series and bearing the Chemical Abstracts Service registry number 1357266-05-7, is a potent and selective partial agonist of trace amine-associated receptor 1 (TAAR1), a Gs protein-coupled receptor expressed on ventral tegmental area dopaminergic neurons, dorsal raphe nucleus serotonergic neurons, and multiple limbic and cortical structures implicated in the regulation of monoaminergic tone, reward processing, and cognition. The compound was identified through iterative medicinal chemistry optimization at the Roche Innovation Center Basel beginning from S18616, a known alpha-2A adrenergic receptor partial agonist, using the Selective Optimization of Side Activities (SOSA) approach to develop highly selective TAAR1 ligands within the 2-aminooxazoline scaffold. RO5263397 activates human TAAR1 with an EC50 of 17 nM and a maximal efficacy (Emax) of 82 percent relative to the endogenous agonist beta-phenylethylamine, achieves 1800-fold selectivity over the alpha-2A adrenergic receptor, and shows no appreciable binding across a panel of 155 receptors, enzymes, and ion channels.

The compound is the most extensively characterized synthetic TAAR1 ligand in the preclinical literature. In rodent and primate models, RO5263397 attenuates cocaine, methamphetamine, nicotine, morphine, and ethanol abuse-related behaviors including self-administration, reinstatement, behavioral sensitization, and conditioned place preference expression; produces antipsychotic-like activity by suppressing phencyclidine-induced and L-687,414-induced hyperlocomotion without inducing catalepsy; enhances novelty recognition memory in both male and female mice through a TAAR1-dependent mechanism confirmed in knockout animals; promotes wakefulness and suppresses NREM and REM sleep through dopaminergic D1/D2 receptor-dependent pathways; exhibits antidepressant-like activity in the forced swim test comparable to fluoxetine; modulates mismatch negativity-like responses in electrophysiological paradigms relevant to schizophrenia; and attenuates aggression and irritability-like behavior in valproic acid and serotonin-deficiency models of autism-related phenotypes. The compound demonstrates zero abuse liability, producing neither self-administration nor conditioned place preference at any tested dose.

Pharmacokinetically, RO5263397 is orally bioavailable with favorable aqueous solubility (5830 micrograms per milliliter), membrane permeability (PAMPA Peff 14.5 times 10 to the minus 6 centimeters per second), and a plasma elimination half-life in rats of 4.3 hours after oral administration. The compound is metabolized predominantly by N-glucuronidation through UGT1A4 and UGT2B10. A pharmacogenomic liability was identified during clinical evaluation: individuals homozygous for a UGT2B10 splice site mutation (prevalence approximately 45 percent in populations of African origin, 8 percent in Asian populations, less than 1 percent in Caucasian populations) exhibit a greater than 100-fold reduction in intrinsic clearance, producing in one clinical trial participant a 136-fold above-average systemic exposure to the parent compound. This metabolic polymorphism led to discontinuation of clinical development of RO5263397, although the TAAR1 target has been advanced by other agonists including ulotaront (SEP-363856) and ralmitaront (RO6889450). The compound remains widely available as a research-grade tool for TAAR1 pharmacology and is supplied by multiple chemical vendors at greater than 98 percent purity by HPLC. This monograph reviews the chemistry, synthesis, discovery history, molecular pharmacology, pharmacokinetics, preclinical pharmacology across addiction, psychosis, cognition, mood, and aggression endpoints, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five TAAR1 ligands against RO5263397 on five competency standards.